tyloxapol has been researched along with Cystic Fibrosis of Pancreas in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (33.33) | 18.2507 |
| 2000's | 1 (33.33) | 29.6817 |
| 2010's | 1 (33.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Beubler, E; Fischer, R; Strohmaier, W; Untersteiner, G | 1 |
| Corcoran, TE; Garoff, S; Marcinkowski, AL; Pilewski, JM; Tilton, RD | 1 |
| Diaz, JL; Ghio, AJ; Hasegawa, T; Kennedy, TP; Marshall, BC; Piantodosi, CA; Povia, D; Samuelson, W | 1 |
3 other study(ies) available for tyloxapol and Cystic Fibrosis of Pancreas
| Article | Year |
|---|---|
Influence of the Surfactant Tyloxapol on Mucociliary Clearance in Human Respiratory Cystic Fibrosis Cells.
Topics: Cystic Fibrosis; Humans; Microspheres; Mucociliary Clearance; Polyethylene Glycols; Polystyrenes; Respiratory Mucosa; Surface-Active Agents; Tissue Culture Techniques | 2016 |
Postdeposition dispersion of aerosol medications using surfactant carriers.
Topics: Aerosols; Animals; Biological Products; Cells, Cultured; Cetrimonium; Cetrimonium Compounds; Cystic Fibrosis; Drug Carriers; Epithelial Cells; Gastric Mucosa; Humans; Models, Biological; Polyethylene Glycols; Pulmonary Surfactants; Sodium Dodecyl Sulfate; Surface-Active Agents; Swine; Tissue Distribution | 2008 |
Tyloxapol inhibits NF-kappa B and cytokine release, scavenges HOCI, and reduces viscosity of cystic fibrosis sputum.
Topics: Adult; Animals; Base Sequence; Cells, Cultured; Cystic Fibrosis; Cytokines; DNA; Free Radical Scavengers; Humans; Hypochlorous Acid; Male; Molecular Sequence Data; Monocytes; NF-kappa B; Polyethylene Glycols; Rats; Rats, Sprague-Dawley; Sputum; Surface-Active Agents; Transcription Factors; Viscosity | 1996 |